PathXL Announces Plans to Create 32 New Jobs in £3.6m Investment


PathXL, the global pioneer in advanced software solutions for digital pathology, is investing £3.6m in growth and creating 32 highly skilled jobs over the next three years.

The Belfast-based company, a Queen’s University spin-out, is undertaking its expansion plan with £390,000 of support from Invest Northern Ireland. The investment is aimed at driving international sales of PathXL’s award-winning tumour detection software TissueMark, developed with R&D assistance from Invest NI.

PathXL’s Chief Executive, Des Speed, said: “Our ultimate aim is to become world famous for contributing something really meaningful to the field of digital pathology. This investment will help us to further develop the new TissueMark automated tumour detection, analysis and identification solution and broaden the exposure of, and interest in, our digital pathology solution concepts.

“Invest NI’s support will mean we can progress our growth plans at a faster pace and greater scale to develop new products and attract new sales.”

Alastair Hamilton, Chief Executive of Invest Northern Ireland, welcomed the news during a visit to the company’s premises at the Northern Ireland Science Park. He said: “This innovative indigenous company is achieving impressive international success within a niche segment of the pathology market. Its investment reinforces the message that Northern Ireland is an attractive and cost-effective location for knowledge-based business.

“These new high-quality jobs will pay above the Northern Ireland private sector median and will generate almost £3m a year in salaries.

“PathXL’s lucrative technology has a multitude of potential applications across the life, health and biological sectors. This investment in market development and workforce will give PathXL the scope to service an expanding market.”

The 32 new roles are in areas including software development, account management, software support and testing, operations and project management.

Invest NI’s R&D support is part funded by the European Regional Development Fund.